Pharma IQ Members

White Papers

Pharma is devoted to providing pharma professionals with the most comprehensive selection of case studies and white papers on the internet. Get in-depth information through Pharma IQ's pharma and biotechnology white papers. Our white papers aim to educate industry leaders as they make complex business decisions that drive growth, innovation and ROI. 

346 whitepaper results
of 34

Counterfeit pharmaceuticals can cause a lot of harm – drug recalls, loss of public confidence, law suits, and risks to patient safety. In the combat against malicious tampering, anti-counterfeiting technology aims to prevent the emergence of counterfeit drugs by creating hurdles to deter by making the task of cloning a drug too complex and expensive.Learn more

Patient Compliance

The packaging, labelling and artwork division of the pharma market faces pressure from a range of directions. Varying country requirements, refreshed regulations, controlling the demanding overheads and arguably the one of the most costly pressures is the combat against pharmaceutical inappropriate use by patients. Pharmaceuticals taken incorrectly are a public safety concern, leading to a significant level of fatalities each year.Learn more


The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.Learn more

Vjet WP2

The Whitepaper outlines the requirements for compliance with the DSCSA, and discusses the challenges facing the pharmaceutical industry. Various strategies will be explored as well as how to take maximum advantage of the supply chain benefits that can be achieved with the right planning and implementation. TLearn more


When examining the known future for GMP compliance, there are a range of changes that the industry needs to brace for, including a new EU delegated act focused on investigational medicinal products. Here Pharma IQ outlines the GMP updates the market will soon be facing.Learn more

P&L report image

According to recent research, the global pharmaceutical packaging market is forecasted to reach more than US$80 billion in revenue by 2020. This expanding market is advancing towards optimization in regards to effectiveness. However, as noted in recent research, this wasn’t always the case: “Packaging was considered as an afterthought which was required merely in the final stages of manufacturing for many pharmaceutical companies about a decade ago. But of late, pharmaceutical packaging has quickly become an essential part of the drug delivery system..” (1)Learn more


Pharma IQ has compiled this resource booklet containing presentations held at the 2015 Medical Device UDIs and Traceability conference on the following subjects: GUDID – The Data Gathering and Maintenance Challenges Re-thinking Your Labelling Processes and Getting the Buy-in from All Stakeholders Evaluating and Determining the Key Components, Planning and Execution of a UDI Project These presentations drill down and examine each of the above challenges in great detail and assess the strategies that can address them.Learn more


While the US advances with its coverage of medical device classes within the U.S. Food and Drug Administration (FDA) Unique Device Identification regime, other countries around the globe are progressing their own track and trace strategies for medical devices. Through the collaboration of the world’s regulatory agencies it is hoped that a synchronized approach to medical device identification will be achieved on an international level, amidst their efforts to tackle counterfeiting, increase accountability and enable safety corrective measures. (2)Learn more


With a view to contribute to the industry’s ongoing progression, Pharma IQ collates the lessons learnt by hospitals during the implementation of UDIs for medical devices and how the conduct of manufacturers and hospitals could be altered to not just optimize this project’s roll out but to avoid incurring any detriment.Learn more


The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now.Learn more

346 whitepaper results
of 34